Currently, there are 190.55M common shares owned by the public and among those 188.22M shares have been available to trade.
The company’s stock has a 5-day price change of -0.83% and -3.46% over the past three months. BMRN shares are trading -30.90% year to date (YTD), with the 12-month market performance down to -30.75% lower. It has a 12-month low price of $61.15 and touched a high of $99.25 over the same period. BMRN has an average intraday trading volume of 1.49 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.23%, 0.15%, and -15.27% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares accounts for 96.64% of the company’s 190.55M shares outstanding.
It has a market capitalization of $12.70B and a beta (3y monthly) value of 0.29. The stock’s trailing 12-month PE ratio is 40.12, while the earnings-per-share (ttm) stands at $1.66. The company has a PEG of 2.01 and a Quick Ratio of 2.62 with the debt-to-equity ratio at 0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.26% over the week and 2.65% over the month.
Earnings per share for the fiscal year are expected to increase by 159.19%, and 43.05% over the next financial year.
Looking at the support for the BMRN, a number of firms have released research notes about the stock. Wolfe Research stated their Outperform rating for the stock in a research note on November 15, 2024, with the firm’s price target at $95. Raymond James was of a view on October 10, 2024 that the stock is Outperform, while Bernstein gave the stock Outperform rating on August 20, 2024, issuing a price target of $94- $110. Robert W. Baird on their part issued Neutral rating on May 17, 2024.
